Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Mantle-Cell 6Unspecified Adult Solid Tumor, Protocol Specific 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Colorectal Neoplasms 5Waldenstrom Macroglobulinemia 4Rectal Neoplasms 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Prolymphocytic 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HTLV-I Infections × Pharmacogenomic Testing × Clear all
NCT02631746 2025-03-14

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
3 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡